D
Arbutus Biopharma Corporation ABUS
$3.34 $0.103.09% NASDAQ
Recommendation
Prev Close
$3.24
Volume
4
Avg Vol (90D)
958,271
Market Cap
$620.40M
Dividend & Yield
--
52-Week Range
$2.63 - $4.73
P/E (TTM)
--
EPS (TTM)
-$0.3807
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Arbutus Biopharma (ABUS, $3.34) price moved above its 50-day Moving Average on April 24, 2025
4/25/2025 - Tickeron - Stocks
JPMorgan Chase & Co. Has $2.93 Million Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS)
4/25/2025 - MarketBeat
Will Arbutus Biopharma (ABUS) Report Negative Q1 Earnings? What You Should Know
4/24/2025 - Zacks Investment Research
Arbutus Biopharma (ABUS, $3.24) Moving Average Convergence Divergence (MACD) Histogram turned positive on April 23, 2025
4/24/2025 - Tickeron - Technical Analysis
Arbutus Biopharma (NASDAQ:ABUS) Trading Up 4.8% - What's Next?
4/23/2025 - MarketBeat
Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025
4/23/2025 - Globe Newswire
Commit To Purchase Arbutus Biopharma At $3, Earn 29.3% Annualized Using Options
4/21/2025 - Stock Options Channel
Franklin Resources Inc. Takes $301,000 Position in Arbutus Biopharma Co. (NASDAQ:ABUS)
4/21/2025 - MarketBeat
Quinn Opportunity Partners LLC Has $1.32 Million Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS)
4/12/2025 - Ticker Report
Arbutus Biopharma (ABUS, $3.17) RSI Indicator left the oversold zone on April 09, 2025
4/10/2025 - Tickeron - Stocks
Arbutus Biopharma (NASDAQ:ABUS) Shares Down 6.3% - Here's What Happened
4/10/2025 - MarketBeat
Arbutus Biopharma (ABUS, $3.01) Moving Average Convergence Divergence (MACD) Histogram turned negative on April 7, 2025
4/8/2025 - Tickeron - Stocks
ADAR1 Capital Management LLC Cuts Stake in Arbutus Biopharma Co. (NASDAQ:ABUS)
4/7/2025 - Ticker Report
Arbutus Biopharma (ABUS, $3.23) price exceeded its 50-day Moving Average on April 04, 2025
4/5/2025 - Tickeron - Stocks
Arbutus Biopharma (ABUS, $3.23) entered Downtrend as Momentum indicator drops below 0 level on Apr 04, 2025
4/5/2025 - Tickeron - Stocks
Rangeley Capital LLC Acquires Shares of 1,459,000 Arbutus Biopharma Co. (NASDAQ:ABUS)
4/5/2025 - MarketBeat
Moderna (NasdaqGS:MRNA) Faces Legal Spotlight Affecting Investor Sentiment with -8% Dip Over Last Month
4/1/2025 - Simply Wall St
Harmony, Lungpacer, Verrica and Arbutus make C-suite hires
4/1/2025 - BizJournals.com - Nat'l Business News
All You Need to Know About Arbutus (ABUS) Rating Upgrade to Buy
3/31/2025 - Zacks Investment Research
Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?
3/31/2025 - Zacks Investment Research
Arbutus Biopharma (NASDAQ:ABUS) Rating Increased to Hold at StockNews.com
3/30/2025 - MarketBeat
Arbutus Biopharma (NASDAQ:ABUS) Issues Quarterly Earnings Results
3/29/2025 - MarketBeat
Arbutus Biopharma (NASDAQ:ABUS) Trading 4.1% Higher Following Strong Earnings
3/29/2025 - MarketBeat
Chardan Capital Reaffirms "Buy" Rating for Arbutus Biopharma (NASDAQ:ABUS)
3/29/2025 - MarketBeat
Arbutus Biopharma (ABUS, $3.5) price moved above its 50-day Moving Average on March 28, 2025
3/29/2025 - Tickeron - Stocks
Income Statement
Total Revenue (TTM)
$6.17M
EBITDA (TTM)
-$72.31M
EBIT (TTM)
-$73.69M
Net Income (TTM)
-$69.92M
Balance Sheet
Total Assets (Q)
$131.71M
Total Debt (Q)
$6.12M
Total Liabilities (Q)
$34.34M
Book Value Per Share (Q)
$0.5126
Cash Flow
Cash from Operations (TTM)
-$64.85M
Cash from Investing (TTM)
$22.95M
Cash from Financing (TTM)
$52.00M
Net Change in Cash (TTM)
$10.05M
Filings
Filing Date
Thursday, March 27, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Beginning of May (est)
Price History
Loading...
Beta
0.72
7-Day Total Return
1.83%
30-Day Total Return
4.70%
60-Day Total Return
-0.30%
90-Day Total Return
-8.24%
Year to Date Total Return
1.52%
1-Year Total Return
21.45%
2-Year Total Return
15.57%
3-Year Total Return
27.00%
5-Year Total Return
176.03%
52-week Low
May 02, 2024 - $2.63
52-week High
Sep 09, 2024 - $4.73
Valuation
Market Cap
$620.40M - Small Cap
Enterprise Value
$503.89M
Price/Sales (TTM)
99.69
Price/Book (Q)
6.32
Dividends and Shares
Shares Outstanding
189.70M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.arbutusbio.com
Phone Number
267 469 0914
Address
701 Veterans Circle
Warminster, PA 18974
Country
United States
Year Founded
2005
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline... more
NASDAQ 04/24/2025 4:00PM Eastern Quotes delayed